The ‘Angelina Jolie effect’
Caroline McGraw Lecturer, Public health, School of Health Sciences, City, University of London
Inherited mutations in the known breast cancer susceptibility genes (BRCA1 and BRCA2) are associated with an increased risk of developing breast and ovarian cancer. In May 2013, Angelina Jolie disclosed she was a carrier of one of these mutations and announced she had undergone a preventive bilateral mastectomy (PBM). Two years later, she announced she had undergone a laparoscopic bilateral salpingo-oophorectomy. This research digest summarises three recent studies evaluating the effect of her disclosure.
Primary Health Care. 28, 1, 14-14. doi: 10.7748/phc.28.1.14.s13
Want to read more?
Subscribe for unlimited access
Try 1 month’s access for just £1 and get:
- Full access to the website and the online archive
- Bi-monthly digital edition
- RCNi Portfolio and interactive CPD quizzes
- RCNi Learning with 200+ evidence-based modules
- 10 articles a month from any other RCNi journal
Already subscribed? Log in
Alternatively, you can purchase access to this article for the next seven days. Buy now